Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings

Intermezzo(R) (zolpidem tartrate sublingual lozenge) developed to be the

first sleep aid specifically for use in the middle of the night when

patients awaken and have difficulty returning to sleep

PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge). Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

The Intermezzo(R) NDA submission follows the successful completion of two Phase 3 clinical trials. The first Intermezzo(R) Phase 3 trial was a double-blind, placebo-controlled crossover sleep laboratory study of 82 patients, which Transcept believes to be among the largest reported sleep laboratory studies of its type. This objective study demonstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, and there was no evidence of next day residual sedative effects with either dose. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep. When patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either Intermezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, commented, "The submission of the Intermezzo(R) NDA achieves a key milestone for the Transcept team and advances our efforts to gain FDA approval for Intermezzo(R) as the first sleep aid developed specifically to be used in the middle of the night when patients awaken and have difficulty returning to sleep. This NDA submission is the latest in a series of transformative events for Transcept, which have recently included our execution of a definitive merger agreement with Novacea, Inc. Assuming that this proposed merger closes near the end of 2008, Transcept is expected to begin 2009 with an estimated cash balance of $88 to $92 million, which we believe will enable us to carry out our plan to successfully commercialize Intermezzo(R)."

Middle of the Night Awakenings & Intermezzo(R)

According to a recent independent study, conducted by Dr. Maurice Ohayon of the Stanford Sleep Epidemiology Research Center, middle of the night awakening is the most frequently reported insomnia symptom. This study estimates that 35% of American adults experience a middle of the night awakening at least three times per week (Journal of Psychiatric Research, in press).

All of the most commonly prescribed sleep aids are designed to produce approximately seven to eight hours of sleep, and can be expected to cause residual sedative effects the next morning if used in the middle of the night with less than eight hours of time remaining in bed. The rapidly absorbed, lower zolpidem dose used in Intermezzo(R) has been developed to treat middle of the night awakenings, to be taken as needed at the time they occur.

Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the proprietary Transcept Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. A bioavailability study has demonstrated that, despite the fact that Intermezzo(R) 3.5 mg contains only about one-third the dose of zolpidem as compared to an Ambien(R) 10 mg tablet, Intermezzo(R) achieved significantly higher overall bioavailability in the first 10 to 20 minutes after administration when compared to the higher Ambien(R) dose.

About the Proposed Transcept and Novacea Merger

On September 2, 2008, Transcept Pharmaceuticals, Inc. and Novacea, Inc. (Nasdaq: NOVC) entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Further information on the merger agreement is available in the last section of this press release, entitled "Additional Information about the Merger and Where to Find It."

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept submitted an NDA to the FDA via the 505(b)(2) pathway on September 30, 2008.

For further information, please visit the company's website at:

About Novacea

Novacea, Inc. is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including Asentar(TM), which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of closing the merger, the expected cash balance of the combined entity as of the closing, the sufficiency of post closing cash to fund development of Intermezzo(R) through planned commercialization and the potential markets and expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the closing of the merger; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, obtaining regulatory approval, market acceptance and commercialization of Intermezzo(R); and the advantages of Intermezzo(R).

Additional Information about the Merger and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between Transcept and Novacea. In connection with the transaction, Novacea will file a registration statement on Form S-4 with the SEC containing a proxy statement/prospectus/information statement. The proxy statement/prospectus/information statement will be mailed to the stockholders of Novacea and Transcept. Investors and security holders of Novacea and Transcept are urged to read the proxy statement/prospectus/information statement when it becomes available because it will contain important information about Novacea, Transcept and the proposed transaction. The proxy statement/prospectus/information statement (when it becomes available), and any other documents filed by Novacea with the SEC, may be obtained free of charge at the SEC web site at In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Novacea by contacting Novacea Investor Relations by e-mail at or by telephone at (650) 228-1800. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Novacea and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in favor of the proposed transaction. Information about the directors and executive officers of Novacea and their respective interests in the proposed transaction will be available in the proxy statement/prospectus/information statement. Intermezzo(R) and Bimucoral(R) are registered trademarks of Transcept Pharmaceuticals, Inc. and Ambien(R) and Ambien CR(R) are registered trademarks of Sanofi-Aventis.


Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington / Jason Rando

(510) 215-3575 (646) 536-7017 / 7025

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
(Date:11/24/2015)... 24, 2015 F1000Workspace - a ... since it was launched just six months ago. --> ... authoring platform for scientists - since it was launched just ... been loaded on to F1000Workspace - a research ... it was launched just six months ago. ...
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology:
(Date:11/24/2015)... VA (PRWEB) , ... November 24, 2015 , ... ... people across the United States to support their local poison centers through donations ... designated as #GivingTuesday: calls it “a day that inspires people to collaborate ...
(Date:11/24/2015)... ... 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance ... some of the staff members at their recovery center. The videos highlight some of ... some of the things that make their recovery program so unique. , “Making the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... 2015 , ... Dr. Rodney E. Willey , has answered a new calling – to ... Disorders, provides treatment for snoring and sleep apnea through oral appliance therapy. ... Sleep Disorders in the US, one of four in the Illinois area. , Dr. ...
Breaking Medicine News(10 mins):